Cord Blood Graft Engineering

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1 SUPPL., 2013, Pages

  Delaney, Colleen ^a   Bollard, Catherine M ^b   Shpall, Elizabeth J ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LEUKEMIA ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOVIRUS; ARTICLE; BIOENGINEERING; BONE MARROW; CANCER PATIENT; CD34 SELECTION; CELL EXPANSION; CELL FATE; CELL HOMING; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELL TYPE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; ENGRAFTMENT; EPSTEIN BARR VIRUS; EX VIVO STUDY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NEUTROPHIL COUNT; NONHUMAN; ORGAN DONOR; OUTCOME ASSESSMENT; PLURIPOTENT STEM CELL; PROPHYLAXIS; SIGNAL TRANSDUCTION; STEM CELL; SURGICAL RISK; UMBILICAL CORD BLOOD; VIRUS STRAIN;

ADOLESCENT; ADULT; CELL ENGINEERING; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FETAL BLOOD; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; MALE; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTS;

EID: 84871891282     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.015     Document Type: Article

References (39)

1. Gluckman E., Ruggeri F., Volt R., et al. Milestones in umbilical cord blood transplantation. Br J Haematol 2011, 154:441-447.
2. Broxmeyer H.E., Lee M.R., Hangoc G., et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood 2011, 117:4773-4777.
3. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276-2285.
4. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
5. Takahashi S., Iseki T., Ooi J., et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004, 104:3813-3820.
6. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005, 105:1343-1347.
7. Dahlberg A., Delaney C., Bernstein I.D. Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood 2011, 117:6083-6090.
8. de Lima M., McMannis J., Gee A., et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 2008, 41:771-778.
9. Frassoni F., Gualandi F., Podesta M., et al. Direct intrabone transplant of unrelated cord blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008, 9:831-839.
10. + cells from an HLA-haploidentical donor. Exp Hematol 2003, 31:535-544.
11. Bautista G., Cabrera J.R., Regidor C., et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant 2009, 43:365-373.
12. Macmillan M.L., Blazar B.R., DeFor T.E., et al. Transplantation of ex vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 2009, 43:447-454.
13. Robinson S.N., Simmons P.J., Thomas M.W., et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Exp Hematol 2012, 40:445-456.
14. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
15. Delaney C., Heimfeld S., Brashem-Stein C., et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010, 16:232-236.
16. Robinson S.N., Ng J., Niu T., et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 2006, 37:359-366.
17. de Lima M., Robinson S., McManins J., et al. Mesenchymal stem cell (MSC)-based cord blood (CB) expansion (Exp) leads to rapid engraftment of platelets and neutrophils. Blood 2010, 116:362.
18. Peled T., Mandel J., Goudsmid R.N., et al. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. Cytotherapy 2004, 6:344-355.
19. + cells cultured with cytokines and promotes their homing and engraftment in SCID mice. Blood 2006, 108:725.
20. Xia L., McDaniel J.M., Yago T., et al. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 2004, 104:3091-3096.
21. North T.E., Goessling W., Walkley C.R., et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007, 447:1007-1011.
22. Hoggatt J., Singh P., Sampath J., et al. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009, 113:5444-5455.
23. Cutler C.S., Shoemaker D., Ballen K.K., et al. FT1050 (16,16-dimethyl prostaglandin E2)-enhanced umbilical cord blood accelerates hematopoietic engraftment after reduced intensity conditioning and double umbilical cord blood transplantation. Blood 2011, 118:653.
24. + progenitor cells. J Immunol 2002, 169:7000-7008.
25. Christopherson K.W., Hangoc G., Mantel C.R., et al. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004, 305:1000-1003.
26. Leen A.M., Myers G.D., Sili U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12:1160-1166.
27. + lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012, 119:2644-2656.
28. Heslop H.E., Slobod K.S., Pule M.A., et al. Long-term outcome of EBV-specific T cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
29. Peggs K.S., Thomson K., Samuel E., et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011, 52:49-57.
30. Hanley P.J., Cruz C.R., Savoldo B., et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114:1958-1967.
31. Park K.D., Marti L., Kurtzberg J., et al. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 2006, 108:1770-1773.
32. Sun Q., Burton R.L., Pollok K.E., et al. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood. Cell Immunol 1999, 195:81-88.
33. Kohn D.B., Dotti G., Brentjens R., et al. CARs on track in the clinic. Mol Ther 2011, 19:432-438.
34. Serrano L.M., Pfeiffer T., Olivares S., et al. Differentiation of naive cord blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 2006, 107:2643-2652.
35. Kochenderfer J.N., Dudley M.E., Feldman S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric antigen receptor-transduced T cells. Blood 2012, 119:2709-2720.
36. Kalos M., Levine B.L., Porter D.L., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
37. Micklethwaite K.P., Savoldo B., Hanley P.J., et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 2010, 115:2695-2703.
38. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
39. Xing D., Ramsay A.G., Gribben J.G., et al. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 ex vivo expansion. J Immunother 2010, 33:684-696.